We have questions about Biogen’s resurrected Alzheimer’s drug
Two days after Biogen unhyperbolically shocked the world by bringing back a once-shelved therapy for Alzheimer’s disease, there are more than a few lingering questions.
As STAT’s Sharon Begley reports, Biogen’s rehabilitation plan has sweeping implications. Does the in-retrospect promise of the therapy mean we should revisit the graveyard of failed treatments past? And does it mean skeptical scientists should retract their eulogies for the amyloid hypothesis?
Or is this all a waste of time? More than a few experts have spotted some confounding details in Biogen’s data, and they’ll be seeking clarity when the company faces the scientific public in December. Then there’s the matter of whether the FDA will buy into all this and, most important, whether unleashing this drug on the public will actually improve people’s lives.
Read more.
As STAT’s Sharon Begley reports, Biogen’s rehabilitation plan has sweeping implications. Does the in-retrospect promise of the therapy mean we should revisit the graveyard of failed treatments past? And does it mean skeptical scientists should retract their eulogies for the amyloid hypothesis?
Or is this all a waste of time? More than a few experts have spotted some confounding details in Biogen’s data, and they’ll be seeking clarity when the company faces the scientific public in December. Then there’s the matter of whether the FDA will buy into all this and, most important, whether unleashing this drug on the public will actually improve people’s lives.
Read more.
No hay comentarios:
Publicar un comentario